[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  BowTiedBiotech 🧪🔬🧬 [@BowTiedBiotech](/creator/twitter/BowTiedBiotech) on x 19.7K followers Created: 2025-07-23 00:11:43 UTC 2/ 📚 The Arena Story: From Ph2 Pop to Ph3 Plateau 1⃣Phase 2b ARISE Study (2018) Arena ($ARNA) lit up the UC space with etrasimod, a selective S1P1 modulator. The Phase 2b ARISE trial showed: 🔹∆15% placebo-adjusted clinical remission @ wk-12 🔹Strong endoscopic and clinical response signals 🔹Clean safety vs ozanimod (less bradycardia, no liver lab burden) Investor reaction: Huge enthusiasm → $ARNA rallies. Etrasimod dubbed “the best-in-class oral” in UC. 2⃣Phase X ELEVATE UC XX / XX (2021–2022) Arena launches a robust Ph3 program: 🔹Dual trials: 12-week induction (UC 12) 🔹52-week combined induction-maintenance (UC 52) 🔹Enrolls bio-naive and bio-experienced patients Induction Results (UC 12): 🔹Clinical remission ∆17% vs PBO (stat-sig) 🔹Similar signals to Ph2 → thesis intact Maintenance Results (UC 52): 🔹Clinical remission benefit persists, but less robust 🔹Placebo remission rose, narrowing deltas 🔹Subgroup analysis atten. benefit in JAK/bio-fail pts 🔹Real-world-like durability concerns emerge 3⃣M&A Outcome Despite these results, Pfizer ($PFE) acquired Arena in Dec 2021 for $6.7B Justified the deal based on: 🔹Solid (not spectacular) UC profile 🔹Pipeline optionality (etrasimod in CD, EoE, derm) 🔹Clean oral S1P w. >cardiac profile than ozanimod Takeaway: Strong UC induction ≠ massive M&A unless: 🔹Maintenance durability holds up 🔹Label is differentiated 🔹Commercial path is compelling BUT WHAT WOULD THIS SCENARIO MEAN FOR $ABVX ????? (see next post) XXXXX engagements  **Related Topics** [investment](/topic/investment) [signals](/topic/signals) [lit](/topic/lit) [$arna](/topic/$arna) [arena](/topic/arena) [Post Link](https://x.com/BowTiedBiotech/status/1947811828588757070)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
BowTiedBiotech 🧪🔬🧬 @BowTiedBiotech on x 19.7K followers
Created: 2025-07-23 00:11:43 UTC
2/ 📚 The Arena Story: From Ph2 Pop to Ph3 Plateau
1⃣Phase 2b ARISE Study (2018)
Arena ($ARNA) lit up the UC space with etrasimod, a selective S1P1 modulator. The Phase 2b ARISE trial showed:
🔹∆15% placebo-adjusted clinical remission @ wk-12 🔹Strong endoscopic and clinical response signals 🔹Clean safety vs ozanimod (less bradycardia, no liver lab burden)
Investor reaction: Huge enthusiasm → $ARNA rallies. Etrasimod dubbed “the best-in-class oral” in UC.
2⃣Phase X ELEVATE UC XX / XX (2021–2022)
Arena launches a robust Ph3 program: 🔹Dual trials: 12-week induction (UC 12) 🔹52-week combined induction-maintenance (UC 52) 🔹Enrolls bio-naive and bio-experienced patients
Induction Results (UC 12): 🔹Clinical remission ∆17% vs PBO (stat-sig) 🔹Similar signals to Ph2 → thesis intact
Maintenance Results (UC 52): 🔹Clinical remission benefit persists, but less robust 🔹Placebo remission rose, narrowing deltas 🔹Subgroup analysis atten. benefit in JAK/bio-fail pts 🔹Real-world-like durability concerns emerge
3⃣M&A Outcome Despite these results, Pfizer ($PFE) acquired Arena in Dec 2021 for $6.7B
Justified the deal based on: 🔹Solid (not spectacular) UC profile 🔹Pipeline optionality (etrasimod in CD, EoE, derm) 🔹Clean oral S1P w. >cardiac profile than ozanimod
Takeaway: Strong UC induction ≠ massive M&A unless: 🔹Maintenance durability holds up 🔹Label is differentiated 🔹Commercial path is compelling
BUT WHAT WOULD THIS SCENARIO MEAN FOR $ABVX ????? (see next post)
XXXXX engagements
Related Topics investment signals lit $arna arena